why does nobody talk about API source
Something I noticed reading old threads that I have not seen said out loud. The advice on 503B in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with the…
Mechanistically the bit that matters is 503B. It explains most of the early profile and a decent chunk of the outcome.
no pharmacy referral codes, naming is fine, recruiting is not
Strongly agree. API source transparency matters.
Did they tell you their API source or dodge the question?
no pharmacy referral codes, naming is fine, recruiting is not
no pharmacy referral codes, naming is fine, recruiting is not
Adding to this: 503B is doing more work than the comment implies.
the shortage list is temporary, it ends and compounding becomes illegal again
Are we talking 503A or 503B?
telehealth prescriber models exist, pricing differs by state
Small correction: the trial was 10 weeks, not 25. Does not change your point but people will quote it.
the Poland situation is different from the US, different regulations